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Protocol
AbstrACt
Introduction Gliomas, the most commonly diagnosed 
primary brain tumours, are associated with varied 
survivals based, in part, on their histological subtype. 
Therefore, accurate pretreatment tumour grading is 
essential for patient care and clinical trial design.
Methods and analysis We will perform an individual-
level data meta-analysis of published studies to evaluate 
the ability of different types of positron emission 
tomography (PET) to differentiate high from low-grade 
gliomas. We will search PubMed and Scopus from 
inception through 30 July 2017 with no language 
restriction and full-text evaluation of potentially relevant 
articles. We will choose studies that assess PET using 
18-Fludeoxyglucose (18F-FDG), l-[Methyl-()11C]Methionine 
(11C-MET), 18F-Fluoro-Ethyl-Tyrosine (18F-FET) or (18)
F-Fluorothymidine (18F-FLT)for grading, verified with 
histological confirmation. We will include both prospective 
and retrospective studies. Bias will be assessed by two 
reviewers with the Quality Assessment of Diagnostic 
Accuracy Studies-2 tool and as per method described by 
Deeks et al.
Ethics and dissemination Ethics approval was not 
applicable, as this is a meta-analytic study. Results of 
the analysis will be submitted for publication in a peer-
reviewed journal.
PrOsPErO registration number CRD42017078649.
bACkgrOund 
Gliomas are among the most commonly 
diagnosed primary brain tumours with an 
estimated annual incidence of over 20 000 
in the USA1. Based on clinical, histological 
and molecular characteristics, gliomas can 
be broadly divided into two major clinical 
subcategories: low grade and high grade.
High-grade gliomas (also called malignant 
gliomas) are rapidly growing tumours and 
include glioblastomas (grade IV), anaplastic 
astrocytomas (grade III), mixed anaplastic 
oligoastrocytomas (grade III) and anaplastic 
oligodendrogliomas (grade III). Despite 
recent advances in multimodality therapies 
including temozolomide, high-grade gliomas 
remain incurable with a median survival of 
less than 3 years for glioblastomas and less 
than 5 years for anaplastic gliomas2.
In contrast, the low-grade gliomas include 
astrocytomas (grade II), oligodendrogliomas 
(grade II) and oligoastrocytomas (grade II) 
and are indolent, with a median survival over 
5 years.3 Treatment of low-grade gliomas 
is evolving and includes maximal tumour 
resection with the option of radiation and 
chemotherapy.4
From the above, it is evident that accurate 
pretherapy histological grading is of para-
mount importance. In the usual clinical 
setting, histology is clarified with conven-
tional CT or MRI, image-guided biopsy/
subtotal surgical resection or near total resec-
tion. Unfortunately, apart from complete 
resection, other approaches are error prone: 
imaging does not provide usable tissue for 
final diagnosis. Biopsies and partial resections 
can misguide, as gliomas can demonstrate 
histological heterogeneity due to histopatho-
logical progression; a tumour often has both 
low-grade and high-grade components. 
Unless total surgical resection is performed, 
strengths and limitations of this study
 ► This is a first of its kind individual patient data meta-
analysis (IPD-MA) aiming to establish the diagnostic 
accuracy of positron emission tomography with 
various tracers for grading of glioma. Individual level 
meta-analysis with pooling of data can provide more 
statistical power to determine differences between 
imaging modalities.
 ► Variability of data obtained from external sources 
and limited number of patients.
 ► Inherent limitations of IPD-MA for data interpretation/
findings might be speculative.
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histological results depend on which part of the tumour 
is sampled.
As much as it is desirable, extensive tumour resection is 
not always feasible in frail patients or those with tumours 
located adjacent to critical structures. Therefore, in 
order to improve tumour grading either non-invasively 
or by better, targeted biopsies, one needs to be able to 
supplement morphological information obtained from 
conventional imaging with tumour-specific functional 
information.
Positron emission tomography (PET) is a useful 
imaging modality that provides additional metabolic 
information to CT-based or MRI-based morphological 
characterisation of tumours. Its usefulness has been 
proven in lung cancer5 and aggressive lymphomas.6 
Several studies have evaluated PET using various tracers 
such as 18-Fludeoxyglucose (18F-FDG), l-[Methyl-()11C]
Methionine (11C-MET), 18F-Fluoro-Ethyl-Tyrosine 
(18F-FET) or (18)F-Fluorothymidine (18F-FLT) for 
pretherapy histological prediction to differentiate high-
grade from low-grade glioma and reported promising 
results.7–9 The sample sizes of these studies, however, 
are typically small, resulting in imprecise estimates of 
diagnostic accuracy and use heterogeneous designs/
protocols for PET assessment, making interpretation of 
the published data difficult. Often, the positivity cut-off 
criteria are defined post hoc to calculate the best pairs 
of sensitivity and specificity for each study and lack 
generalisability. In this situation, aggregate-level data 
meta-analysis (ALD-MA) typically calculates overesti-
mated summary statistics.
A useful approach to the above problem to perform 
a meta-analysis based on individual-level data (individ-
ual-level data meta-analysis (ILD-MA)). This technique 
employs a predefined uniform cut-off value to estimate 
test performance measures for all included studies and 
combines their results. ILD-MA can also evaluate the 
effect of specific factors on test performance at the level 
of individual, simultaneously accounting for between-
study variations. We therefore planned an ILD-MA to 
provide a comprehensive overview and quantitative 
synthesis of information on the test performance of PET 
for this purpose.
MEthOds
This meta-analysis is an extension of a part of a series 
of systematic reviews on PET in clinical management of 
patients with glioma.10 11 Although these reviews share a 
common literature search until June 2011, each project 
employs an independent prespecified research protocol 
with standard systematic review methodologies and 
assesses mutually exclusive research objectives. Interim 
results of an earlier related study of this research project 
have been presented at an international meeting12 but 
never published as full text.
Literature search
We will use our literature database of publications on 
PET assessed for patients with glioma. We established the 
database based on the searches of PubMed and Scopus 
from inception through 30 June 2011 with no language 
restriction and full-text evaluation of potentially relevant 
articles found though abstract screening. The complete 
search strategy and full list of the database is reported 
elsewhere11 and also available as a online Supplementary 
file. We will update the searches until 30 July 2017 and 
examine the reference lists of eligible studies and rele-
vant review articles.
One reviewer (TN or NAT) will screen abstracts and 
at least two of three investigators (TT, NAT and TT) 
examine full-text articles of potentially eligible citations. 
Discrepancies will be resolved by consensus.
Inclusion and exclusion criteria
We will select studies that assess PET using 18F-FDG, 
11C-MET, 18F-FET or 18F-FLT for predicting glioma 
grading, verified with histological confirmation by surgery 
or biopsy to be eligible. We have selected these four partic-
ular tracers before conducting this research on the basis 
of an empirical evaluation of published studies of PET on 
glioma11 and recently published narrative reviews.13 14 We 
will include both prospective and retrospective studies. We 
will define pathological confirmation (either by biopsy or 
surgical resection) as the acceptable reference standard 
and explicitly exclude studies (or individual patients in 
a study) in which (or for whom, respectively) patholog-
ical confirmation is not performed. We will consider the 
total surgical resection as the (nearly) perfect reference 
standard, whereas (stereotactic) biopsy will be deemed to 
be the imperfect reference standard. We will include any 
language publications that evaluated at least 10 patients 
for whom PET scanning and histopathological confir-
mation is successfully performed. We will exclude edito-
rials, comments, letters to the editor and review articles. 
When multiple publications with potentially overlapping 
patient populations are available, we will only include the 
publication with the largest sample size.
We will contact study authors by email if studies do 
not report adequate information on PET and histolog-
ical results in the participant level or if ILD data are not 
presented in the paper. We will consider our request to be 
rejected if two email request reminders separately sent 14 
days after the initial contact attempt are rejected. Even in 
this case, we will allow for the inclusion of a study report 
in which quantitative data is not reported but the digital 
extraction (ie, data extraction by using a digitizer from its 
published graphical presentations) is feasible. Otherwise, 
we will exclude these studies. Data will be kept in a shared 
secure folder accessible by all co-authors.
data extraction
One reviewer (TN or NAT) will extract descriptive data 
from each eligible study. Another one non-overlapping 
investigator (TN, NAT or TT) will verify all the extracted 
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data. We will extract the following published descriptive 
information from eligible studies: first author, year of 
publication, journal, patient demographics and clinical 
characteristics, therapeutic interventions in the case of 
post-therapy or recurrence assessment, technical specifi-
cations of PET and interpretation of PET results.
One reviewer (TN or NAT) will extract published 
quantitative data regarding imaging results (ie, visual 
assessment and quantitative assessment such as standard 
uptake values (SUVs) or tumour-to-normal uptake ratio 
(T/N ratio)) and final diagnoses (ie, histopathological 
subtype and grading) at the individual level. Another 
one reviewer (TT) will verify all the data. We will exclude 
any cases in which PET scanning is unsuccessful (and 
thus results are arbitrary imputed post hoc). We will also 
exclude any cases in which alternative reference stan-
dards such as clinical follow-up instead of pathological 
confirmation is used to determine histological grading.
If reported, we will also extract the following individu-
al-level variables as the candidate effect modifiers to be 
evaluated in meta-regression: age, sex, clinical scenario 
(ie, primary diagnosis vs post-therapy/recurrence assess-
ment) and tissue sampling methods (ie, how the patho-
logical specimens are obtained, either biopsy, partial or 
total resection).
Assessment of risk of bias
To assess the risk of bias and applicability of each study, 
two reviewers (TN and NAT) will independently assess 
patient selection, index test, reference standard and their 
flow and timing based on the revised Quality Assessment 
of Diagnostic Accuracy Studies 2. Methods to detect publi-
cation bias are not very reliable when used in diagnostic 
accuracy data, especially in case of heterogeneity, but we 
will use the method of Deeks et al15 that has been shown 
to be the least biased. Discrepant ratings will be resolved 
by consensus. The complete list of operational definitions 
to rate each item is available from the authors on request.
data synthesis
We will use a bivariate model to obtain an estimate of 
the summary sensitivity and specificity with their corre-
sponding CIs. We will fit a two-level generalised mixed 
regression model conditional on the sensitivity and 
specificity of each study and a bivariate normal model 
for the sensitivity and specificity between studies16. We 
will calculate summary positive and negative likelihood 
ratios (LRs) based on the summary sensitivity and speci-
ficity estimates. Positive LR (LR+) is the ratio of sensitivity 
over (1−specificity), whereas negative LR (LR−) is defined 
as the ratio of (1−sensitivity) over specificity. The discrim-
inating ability of a diagnostic test is better with higher 
LR+ and lower LR−. A good diagnostic test typically has 
LR+ >5.0 and LR− <0.2. We will also construct a hierar-
chical summary receiver operating characteristic curve 
(HSROC) based on the parameters of the fitted model. 
We will assess between-study heterogeneity visually using 
forest plots and also by plotting sensitivity and specificity 
in the ROC space. We will construct 95% credible regions 
for summary sensitivity and specificity from the estimated 
parameters as proposed.17
subgroup analysis and meta-regression
To explore heterogeneity, we will perform subgroup 
analyses and if feasible, the statistical differences among 
mutually exclusive subgroups will be assessed by univari-
able meta-regression. We will add a candidate modi-
fier (as either 0 (absence) or 1 (presence)) to the test 
performance parameters (ie, sensitivity and specificity 
parameters or diagnostic OR and threshold parameters, 
respectively) jointly in the bivariate random-effects model 
or binormal random-effects model, respectively.
We will record: publication year, study design (ie, 
prospective vs retrospective) as the study-level covariates, 
age, sex, clinical scenario (ie, primary diagnosis vs post-
therapy/recurrence assessment) and tissue sampling 
methods (ie, biopsy vs partial or subtotal resection vs total 
resection).
Comparisons among different PEt methodologies
We will compare the test performance among alternative 
PET tracers and also those based on different imaging 
assessment protocols (ie, visual assessment vs quantitative 
assessment, either T/N ratios or SUVs). Regarding the 
T/N ratios, we will operationally define three categories 
based on the specified referent tissues: mean or median 
uptakes in the grey matter (GM), those in the white 
matter (WM) and other miscellaneous (MISC) methods 
including mean or median uptakes in the contralateral 
corresponding anatomical sites or those in the adjacent 
normal tissue regardless of GM or WM.
For indirect comparisons, we will visually compare 
the constructed summary ROC curves and the credible 
regions of sensitivity and specificity. We will also statisti-
cally assess the differences by univariable meta-regression 
using the tracers or assessment methods as the covariate 
being incorporated into the meta-analytic model. These 
results, however, need to be interpreted carefully because 
findings from the indirect comparisons may be only 
speculative. To tackle this issue, we will also perform these 
analyses limiting only to comparative studies that assess 
multiple tracers or methods for the same participants, 
from which direct comparisons can be performed.
We will conduct all analyses using STATA V.14/SE and 
OpenBUGS V.3.2.3 (members of OpenBUGS Project 
Management Group; see www. openbugs. net). All tests will 
be two-sided and statistical significance will be defined as 
a P value <0.05.
dIsCussIOn
Differentiating high from low-grade malignancies 
has significant prognostic information for a variety of 
tumours; gliomas are not an exception. While an opti-
mally resected biopsy specimen is always preferable to 
indirect evidence, imaging can provide helpful adjunct 
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information. Moreover, functional imaging, such as 
PET with select biotracers, has the potential to become 
a powerful tool in assessment of patients and influence 
treatment decisions. By conducting an IPD meta-analysis, 
this study hopes to clarify the diagnostic accuracy of PET/
CT with various tracers in differentiating glioma histology 
and establish thresholds, on which further studies can be 
performed.
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